GLP-1 drugs linked to improved breast cancer survival, VCU Massey-led study finds

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A research team led by investigators at Virginia Commonwealth University found evidence suggesting there is a positive association between GLP-1 agonists—drugs commonly used to treat obesity and diabetes—and better outcomes among breast cancer patients.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Researchers at VCU Massey Comprehensive Cancer Center led an international effort to create a multi-omic atlas of oral tissues with the aim of advancing the understanding of the immunoregulatory nature of human oral tissues. Recent analyses using data from this atlas suggest that fibroblasts may serve as the core regulators of structural immunity in the mouth.
Malcolm V. Brock, director of Clinical and Translational Research in Thoracic Surgery at Johns Hopkins Kimmel Comprehensive Cancer Center, grew up in Bermuda. His father insisted that his children branch outside the small island—the country has a population of just over 60,000 people—and challenge themselves abroad.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login